Despite the availability of NAC as the primary therapeutic agent for APAP overdose, treatment options remain limited, particularly when administered beyond the early therapeutic window
Wegovy is an injectable weight-loss medication containing the drug semaglutide, a GLP-1 receptor agonist that helps regulate appetite and food intake
Gastrointestinal side effects are the most commonly reported and include: Nausea affects a significant proportion of patients, particularly during dose escalation Diarrhoea may be mild to moderate and usually improves with time Vomiting less common than nausea but can occur, especially at higher doses Constipation some patients experience reduced bowel movements Abdominal pain or discomfort typically mild but should be monitored Reduced appetite contributes to weight loss but may be excessive in some individuals These gastrointestinal symptoms are generally most pronounced when initiating treatment or increasing the dose
muciniphila is a mucin-degrading, acetate and propionate-producing bacterium residing in the mucus layer, thus being in relative close proximity to the intestinal epithelial layer (195), hence having the potential capacity to activate GPR43
Our patients experience lasting weight loss through programs that target metabolism, energy, and overall wellness
